SELLAS Life Sciences Group, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
SELLAS announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia. GPS demonstrated a statistically significant 41% reduction in risk of death (hazard ratio 0.59, p=0.035) with median overall survival of 24.0 months versus 14.7 months for best available treatment in 126 randomized patients. The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.
Why this rating
Phase 3 primary endpoint success for lead product is transformational; potential regulatory path to market. Relative to $219M market cap, approval of GPS could be highly material. Execution risk remains on FDA interaction and BLA.
Tradability signal
SHORT
conviction 20/100 · expected -0.42% over 4 hrs
SHORT (fade the pop): stock already ran +158.5% on this news, and positive calls in this cell have historically given the pop back (-0.44% over 4 hrs, n=515). Reversion play, lower conviction by design. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $8.00 ▼ 65.43% | at our read · unknown $23.14 | +10 min · unknown $20.68 ▼ 10.63% | +30 min · unknown $18.26 ▼ 21.09% | +1 hr · unknown $19.47 ▼ 15.86% | +4 hrs · unknown $19.39 ▼ 16.21% |
The stock had already moved +189.25% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.